Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Skrit37on Nov 08, 2020 5:38am
288 Views
Post# 31859027

RE:Q3 Results

RE:Q3 Results
LittleGuy2 wrote: As we await Q3 results and the hype builds on this forum with all its usual hyperbole, I just want to put it out there that my hope is for modest revenue.  Not the multi-million $ bonanza predicted by many SH pundits, but modest, stable revenue built on good operating practices.  Without quality accessioning, accurate reporting, no contaminated flume hoods (think NFL), and excellence in customer service, Stage will lose ground in any attempts to succeed as a cancer company. Customers will come for the Covid but not stay for the cancer if the service is not top notch.

So I am hoping at this stage the company is paying attention to the quality dial & not the bank account.  I am assuming the institutional investors are likewise steering the Stage board in that direction.



No need to worry about Quaility good sir.....in the Q2 Presentation, Mr Tripp made a point  literally the very first paragraph after the forward looking statements.....

"I think as we focus on company overview, Its important to remember first and foremost that we are a cancer testing company. This is what we do. As a result of that everything we do has to be extremily accurate, everything has to be extremly well done, it has to be very timely. This is how we approarch everything, including the Covid Testing, remeber too, that evrything is focused around Aristotle"

https://www.webcaster4.com/Player/Index?webcastId=36633&g=ee1c8cbb-69e4-4cc3-8a3a-304098741711&uid=5328840&sid=



Bullboard Posts